Bayer’s Supreme Court Victory Reshapes the Legal Landscape — But the July 9 Hearing Will Test Whether the Rally Can Hold

The U.S. Supreme Court handed Bayer a landmark win on June 25, effectively closing the most potent legal avenue for tens of thousands of Roundup lawsuits. The stock surged 23% in the ensuing days, closing the week at €46.61 — a level that sits just 7% below the 52-week high of €49.93. Yet for all the euphoria, the real test comes next week when a federal judge in Missouri must decide whether to approve a $7.25 billion class-action settlement that would cap Bayer’s remaining exposure.

What the Supreme Court Actually Changed

The justices ruled 7-2 in favor of Monsanto on a narrow but pivotal jurisdictional question: only the federal Environmental Protection Agency can mandate cancer warnings on pesticide labels, not individual states or juries. This strips the legal foundation from the vast majority of untried Roundup cases, which relied on state-law failure-to-warn claims. The decision does not erase the $10 billion Bayer has already paid in settlements, nor does it cancel the €11.8 billion in provisions still on the balance sheet. What it does do is make the unresolved legal risk far more predictable.

The July 9 Hurdle

The single most important near-term catalyst is the final fairness hearing for a sweeping class-action settlement, scheduled for July 9 in Missouri. That deal commits Bayer to paying up to $7.25 billion over as many as 21 years in declining annual installments. It stems from the King v. Monsanto case, which was sent back to state court by a federal judge in mid-June after an earlier procedural setback. If the judge approves the settlement, Bayer will have sealed the lid on the largest remaining pool of claims. If he rejects it — or if plaintiffs’ lawyers successfully challenge the terms — the stock’s recent rally could unwind swiftly.

A Cash Squeeze That Won’t Quit

The legal victories have not yet reached the bank account. Free cash flow was negative €2.3 billion in the first quarter of 2026, driven almost entirely by litigation payments. Bayer expects to spend roughly €5 billion on legal costs for the full year. Net financial debt could climb to €33 billion by year-end. That tight liquidity leaves the company with almost no buffer for further legal surprises.

The balance sheet is also weighed down by the aftermath of the Monsanto acquisition. Cumulative settlement payments have reached €10 billion, with another €7 billion provisioned. CFO Judith Hartmann, who took over on June 1, is under investor pressure to impose strict cost discipline. Her first major test will come with the second-quarter earnings report in August, when management must update its net debt forecast in light of the Supreme Court ruling.

Should investors sell immediately? Or is it worth buying Bayer?

Pharma Pipeline Carries the Weight

Operationally, the company is holding up. Group revenue grew a currency-adjusted 4% in the first quarter to €13.4 billion, while EBITDA before special items rose 9% to €4.45 billion. But the strategic pressure point is the pharmaceuticals division. Xarelto, Bayer’s top-selling blood thinner, lost patent protection in 2025 and saw sales plunge by a third to $2.6 billion. The future rests on its successor, asundexian, a Factor XIa inhibitor. The FDA accepted the regulatory filing in May 2026 and granted priority review based on the OCEANIC-STROKE Phase III data. China followed with the same designation. Competition is close behind — Bristol Myers Squibb and Johnson & Johnson are developing milvexian — but Bayer holds the regulatory lead.

In a separate move to strengthen the pipeline, Bayer announced a partnership with Iambic Therapeutics to apply artificial intelligence to small-molecule drug discovery. Traditional R&D in this area can cost $2.6 billion and take more than a decade. The goal is to dramatically compress that timeline, though it will be years before any candidates reach the clinic.

The Technical Picture: Overheated but Not Broken

The stock’s 23% weekly gain pushed the relative strength index to 80.6 — deep into overbought territory. The current price is 27.4% above the 200-day moving average of €36.59, an unusually wide spread that often precedes a pullback. A consolidation after such a rapid move would be entirely normal, and traders will watch for profit-taking ahead of the July 9 hearing.

CEO Bill Anderson has set a goal of significantly reducing U.S. litigation by the end of the year. The Supreme Court ruling is a critical milestone on that path, but it is not the finish line. Between the Missouri hearing, the ongoing EMA review of asundexian, and the August quarterly report, three events in the next two months will determine whether the stock’s breakout is the beginning of a structural re-rating or just a temporary reprieve from legal overhang.